Drug Profile
Research programme: cancer immunotherapeutics adoptive ex vivo - GlaxoSmithKline
Alternative Names: Cancer adoptive immunotherapeutics - GlaxoSmithKline; Cancer adoptive immunotherapy - GlaxoSmithKline; Cancer immunotherapeutics - GlaxoSmithKline; ex vivo cancer immunotherapeutics - GlaxoSmithKlineLatest Information Update: 21 Jan 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 21 Jan 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 20 Sep 1999 Preclinical development for Cancer in USA (Unknown route)